Acrivon Therapeutics, Inc. Common Stock Income Statement
Concept
Total Revenue
YoY
Cost of Goods Sold (COGS)
Gross Profit
Operating expenses
Selling, General & Administrative
Research & Development
Operating Income
Interest Expense
Income Before Tax
Tax Provision
Net Income
YoY
Total Expenses
Net Interest Income
EBITDA
Reconciled Depreciation
EBIT
2023
2022
2021
2020
0M
-
1M
-1M
67M
21M
45M
-67M
0M
-60M
0M
-60M
103.48%
67M
0M
-67M
1M
-67M
0M
-
1M
-1M
33M
9M
24M
-33M
1M
-31M
0M
-30M
82.71%
33M
0M
-32M
0M
-33M
0M
-
1M
-1M
16M
2M
14M
-16M
0M
-16M
0M
-16M
206.13%
16M
0M
-16M
0M
-16M
0M
-
0M
0M
3M
1M
2M
-3M
0M
-5M
0M
-5M
206.13%
3M
0M
-3M
0M
-3M
Concept
Total Revenue
YoY
Cost of Goods Sold (COGS)
Gross Profit
Operating expenses
Selling, General & Administrative
Research & Development
Operating Income
Interest Expense
Income Before Tax
Tax Provision
Net Income
YoY
Total Expenses
Net Interest Income
EBITDA
Reconciled Depreciation
EBIT
4Q2023
3Q2023
2Q2023
1Q2023
4Q2022
3Q2022
2Q2022
1Q2022
4Q2021
3Q2021
2Q2021
1Q2021
0M
-
0M
0M
21M
0M
15M
-21M
0M
-19M
0M
-19M
143.30%
21M
0M
-21M
0M
-21M
0M
-
0M
0M
16M
6M
10M
-16M
0M
-14M
0M
-14M
64.00%
16M
0M
-16M
0M
-16M
0M
-
0M
0M
16M
5M
11M
-16M
0M
-14M
0M
-14M
143.46%
16M
0M
-15M
0M
-16M
0M
-
0M
0M
14M
5M
10M
-14M
-2M
-13M
0M
-11M
53.83%
14M
0M
-14M
0M
-14M
0M
-
0M
0M
10M
4M
6M
-10M
-1M
-9M
0M
-8M
79.19%
10M
0M
-10M
0M
-10M
0M
-
0M
0M
10M
2M
8M
-10M
0M
-9M
0M
-9M
299.32%
10M
0M
-9M
0M
-10M
0M
-
0M
0M
6M
2M
4M
-6M
0M
-6M
0M
-6M
299.32%
6M
0M
-6M
0M
-6M
0M
-
0M
0M
7M
1M
6M
-7M
0M
-7M
0M
-7M
299.32%
7M
0M
-7M
0M
-7M
0M
-
0M
0M
4M
1M
3M
-4M
0M
-4M
0M
-4M
299.32%
4M
0M
-4M
0M
-4M
0M
-
0M
0M
3M
0M
2M
-3M
0M
-2M
0M
-2M
299.32%
3M
0M
-3M
0M
-3M
0M
-
0M
0M
0M
0M
0M
0M
0M
0M
0M
0M
299.32%
0M
0M
0M
0M
-5M
0M
-
0M
0M
0M
0M
0M
0M
0M
0M
0M
0M
299.32%
0M
0M
0M
0M
-5M